JOHNSON & JOHNSON

JNJ Healthcare & Pharma 1/10 Low Risk
1/10

JOHNSON & JOHNSON has $32.4B in total long-term debt with $41.4B in scheduled maturities. Approximately $2.0B (5% of maturities) is due within the next twelve months, and operating income covers interest expense 81.7x. Overall, JNJ carries low refinancing risk (score 1/10).

Maturity Schedule

Year 1 $2.0B Year 2 $3.2B Year 3 $3.1B Year 4 $2.2B Year 5 $2.7B Beyond 5 $28.3B
Period Amount Due % of Total
Year 1 (0-12 months) $2.0B 4.8%
Year 2 (12-24 months) $3.2B 7.8%
Year 3 (24-36 months) $3.1B 7.5%
Year 4 (36-48 months) $2.2B 5.2%
Year 5 (48-60 months) $2.7B 6.5%
Beyond 5 Years $28.3B 68.2%
Total Scheduled Maturities $41.4B 100.0%

Key Metrics

Total Long-Term Debt
$32.4B
Near-Term (12mo)
$2.0B
Interest Coverage
81.7x
Debt/Equity
N/A
Cash Coverage
12.05x
Operating Income
$15.0B

Score Components

Component Value Weight
Near-Term Maturity Concentration 4.8% 30%
Interest Coverage Ratio 81.72x 25%
Debt-to-Equity Ratio N/A 25%
Cash Coverage of Near-Term Debt 12.05x 20%

Related Companies

PFIZER INC
PFE
5/10
Debt: $4.0B 12mo: N/A
AbbVie Inc.
ABBV
5/10
Debt: $64.5B 12mo: $6.0B
Merck & Co., Inc.
MRK
3/10
Debt: N/A 12mo: $2.6B
ELI LILLY & Co
LLY
3/10
Debt: $19.1B 12mo: $781M
BRISTOL MYERS SQUIBB CO
BMY
4/10
Debt: $49.4B 12mo: $2.0B
AMGEN INC
AMGN
5/10
Debt: $60.1B 12mo: $4.6B
GILEAD SCIENCES, INC.
GILD
4/10
Debt: $26.7B 12mo: $2.8B
REGENERON PHARMACEUTICALS, INC.
REGN
1/10
Debt: N/A 12mo: N/A

Data Source: Financial data sourced from SEC EDGAR XBRL filings (10-K annual reports). Most recent filing date: 2026-02-11. Data last fetched: 2026-03-15. Maturity schedules reflect the company's most recently reported debt repayment obligations. Data quality: Partial.